Final results of the NCRI CIL210 trial of Alemtuzumab, Dexamethasone and Lenalidomide in patients with high-risk CLL (original protocol)
Andrew Pettitt, Fotios Polydoros, James Dodd, Melanie Oates, Ke Lin, Nagesh Kalakonda, Helen McCarthy, Adrian Bloor, Anna Schuh, Andrew Duncombe, Claire Dearden, Christopher Fegan, Ben Kennedy, Christina Yap, Sarah E. Coupland, Peter Hillmen
Research output: Chapter in Book/Report/Conference proceeding › Conference contribution
Fingerprint
Dive into the research topics of 'Final results of the NCRI CIL210 trial of Alemtuzumab, Dexamethasone and Lenalidomide in patients with high-risk CLL (original protocol)'. Together they form a unique fingerprint.